{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:57:08Z","timestamp":1791435428104,"version":"4.3.3"},"reference-count":34,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T00:00:00Z","timestamp":1332374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1258,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Statistics in Medicine"],"published-print":{"date-parts":[[2012,7,10]]},"abstract":"<jats:p>Shift in research and development strategy from developing follow\u2010on or \u2018me\u2010too\u2019 drugs to differentiated medical products with potentially better efficacy than the standard of care (e.g., first\u2010in\u2010class, best\u2010in\u2010class, and bio\u2010betters) highlights the scientific and commercial interests in establishing superiority even when a non\u2010inferiority design, adequately powered for a pre\u2010specified non\u2010inferiority margin, is appropriate for various reasons. In this paper, we propose a group sequential design to test superiority at interim analyses in a non\u2010inferiority trial. We will test superiority at the interim analyses using conventional group sequential methods, and we may stop the study because of better efficacy. If the study fails to establish superior efficacy at the interim and final analyses, we will test the primary non\u2010inferiority hypothesis at the final analysis at the nominal level without alpha adjustment. Whereas superiority\/non\u2010inferiority testing no longer has the hierarchical structure in which the rejection region for testing superiority is a subset of that for testing non\u2010inferiority, the impact of repeated superiority tests on the false positive rate and statistical power for the primary non\u2010inferiority test at the final analysis is essentially ignorable. For the commonly used O'Brien\u2013Fleming type alpha\u2010spending function, we show that the impact is extremely small based upon Brownian motion boundary\u2010crossing properties. Numerical evaluation further supports the conclusion for other alpha\u2010spending functions with a substantial amount of alpha being spent on the interim superiority tests. We use a clinical trial example to illustrate the proposed design. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/sim.5312","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T06:15:31Z","timestamp":1332483331000},"page":"1531-1542","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Testing superiority at interim analyses in a non\u2010inferiority trial"],"prefix":"10.1002","volume":"31","author":[{"given":"Y.H.","family":"Joshua Chen","sequence":"first","affiliation":[{"name":"Merck Research Laboratories  Rahway, NJ PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories  Rahway, NJ PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(82)90024-1"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-6-200009190-00014"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-6-200009190-00014"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1425"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710163371610"},{"key":"e_1_2_8_7_1","unstructured":"US Food and Drug Administration.Draft Guidance for Industry: Non\u2010inferiority Clinical Trials March 2010."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb0911104"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39308.560069.BE"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543409508835115"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/CVM-1-1-019"},{"key":"e_1_2_8_12_1","unstructured":"European Agency for the Evaluation of Medicinal Products:EMEA: Points to consider on switching between superiority and non\u2010inferiority\u2014Committee for Proprietary Medical Products 2000.http:\/\/www.emea.europa.eu\/pdfs\/human\/ewp\/048299en.pdf."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60918-1"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318157131c"},{"key":"e_1_2_8_15_1","unstructured":"DemeterL HughesM FischlM GrimesJ BoschR SquiresK HammerS.Predictors of virologic and clinical responses to indinavir (IDV) + ZDV + 3TC or ZDV + 3TC Abstract 509 5thConference on Retroviruses and Opportunistic Infections Chicago IL 1998."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-1036"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8711"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-44-526-793"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1976.220"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2307\/2336502"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/64.2.191"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2307\/2530245"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543409408835080"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2307\/2532600"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2307\/2531438"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.820"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/1541-0420.00013"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2357"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3790"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/68.1.316"},{"key":"e_1_2_8_32_1","unstructured":"ReboussinDM DeMetsDL KimKM LanKKG.Programs for computing group sequential boundaries using the Lan\u2010DeMets method.Tech Report Department of Biostatistics and Medical Informatics University of Wisconsin \u2010 Madison 1996."},{"key":"e_1_2_8_33_1","unstructured":"US Food and Drug Administration.Guidance for industry: antiretroviral drugs using plasma HIV\u2010RNA measurements\u2014clinical considerations for accelerated and traditional approval 2002."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780111012"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.2307\/3214581"}],"container-title":["Statistics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsim.5312","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sim.5312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T22:35:36Z","timestamp":1698705336000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/sim.5312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,22]]},"references-count":34,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,7,10]]}},"alternative-id":["10.1002\/sim.5312"],"URL":"https:\/\/doi.org\/10.1002\/sim.5312","archive":["Portico"],"relation":{},"ISSN":["0277-6715","1097-0258"],"issn-type":[{"value":"0277-6715","type":"print"},{"value":"1097-0258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,22]]}}}